ACE2 expression is increased in the lungs of patients with COVID-19 comorbidities (Pinto et al., 2020), as well as in diabetes (Herman-Edelstein et al., 2021; Vergara et al., 2021) and heart failure (Khoury et al., 2021). This evidence concerns the gene ACE2 and COVID-19.